189 related articles for article (PubMed ID: 31765734)
1. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
Ríos-Luci C; Díaz-Rodríguez E; Gandullo-Sánchez L; Díaz-Gil L; Ocaña A; Pandiella A
Cancer Lett; 2020 Feb; 470():161-169. PubMed ID: 31765734
[TBL] [Abstract][Full Text] [Related]
2. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
3. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
[TBL] [Abstract][Full Text] [Related]
4. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
5. A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
Franco YL; Ramakrishnan V; Vaidya TR; Mody H; Perez L; Ait-Oudhia S
J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):273-293. PubMed ID: 33389550
[TBL] [Abstract][Full Text] [Related]
6. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
[TBL] [Abstract][Full Text] [Related]
7. A gene expression profile indicative of early stage HER2 targeted therapy response.
O'Neill F; Madden SF; Clynes M; Crown J; Doolan P; Aherne ST; O'Connor R
Mol Cancer; 2013 Jul; 12():69. PubMed ID: 23816254
[TBL] [Abstract][Full Text] [Related]
8. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
Brasó-Maristany F; Griguolo G; Pascual T; Paré L; Nuciforo P; Llombart-Cussac A; Bermejo B; Oliveira M; Morales S; Martínez N; Vidal M; Adamo B; Martínez O; Pernas S; López R; Muñoz M; Chic N; Galván P; Garau I; Manso L; Alarcón J; Martínez E; Gregorio S; Gomis RR; Villagrasa P; Cortés J; Ciruelos E; Prat A
Nat Commun; 2020 Jan; 11(1):385. PubMed ID: 31959756
[TBL] [Abstract][Full Text] [Related]
10. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
11. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
12. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
Ding X; Sharko AC; McDermott MSJ; Schools GP; Chumanevich A; Ji H; Li J; Zhang L; Mack ZT; Sikirzhytski V; Shtutman M; Ivers L; O'Donovan N; Crown J; Győrffy B; Chen M; Roninson IB; Broude EV
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2201073119. PubMed ID: 35914167
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Conlon NT; Kooijman JJ; van Gerwen SJC; Mulder WR; Zaman GJR; Diala I; Eli LD; Lalani AS; Crown J; Collins DM
Br J Cancer; 2021 Mar; 124(7):1249-1259. PubMed ID: 33473169
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
[TBL] [Abstract][Full Text] [Related]
17. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Canonici A; Gijsen M; Mullooly M; Bennett R; Bouguern N; Pedersen K; O'Brien NA; Roxanis I; Li JL; Bridge E; Finn R; Siamon D; McGowan P; Duffy MJ; O'Donovan N; Crown J; Kong A
Oncotarget; 2013 Oct; 4(10):1592-605. PubMed ID: 24009064
[TBL] [Abstract][Full Text] [Related]
18. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2
Xu X; De Angelis C; Burke KA; Nardone A; Hu H; Qin L; Veeraraghavan J; Sethunath V; Heiser LM; Wang N; Ng CKY; Chen ES; Renwick A; Wang T; Nanda S; Shea M; Mitchell T; Rajendran M; Waters I; Zabransky DJ; Scott KL; Gutierrez C; Nagi C; Geyer FC; Chamness GC; Park BH; Shaw CA; Hilsenbeck SG; Rimawi MF; Gray JW; Weigelt B; Reis-Filho JS; Osborne CK; Schiff R
Clin Cancer Res; 2017 Sep; 23(17):5123-5134. PubMed ID: 28487443
[No Abstract] [Full Text] [Related]
19. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
20. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
